Biotest Aktiengesellschaft (BIO) - Total Assets
Based on the latest financial reports, Biotest Aktiengesellschaft (BIO) holds total assets worth €1.42 Billion EUR (≈ $1.66 Billion USD) as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See BIO total equity for net asset value and shareholders' equity analysis.
Biotest Aktiengesellschaft - Total Assets Trend (2002–2024)
This chart illustrates how Biotest Aktiengesellschaft's total assets have evolved over time, based on quarterly financial data.
Biotest Aktiengesellschaft - Asset Composition Analysis
Current Asset Composition (December 2024)
Biotest Aktiengesellschaft's total assets of €1.42 Billion consist of 56.5% current assets and 43.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 7.5% |
| Accounts Receivable | €201.90 Million | 14.1% |
| Inventory | €479.50 Million | 33.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €10.50 Million | 0.7% |
| Goodwill | €6.00 Million | 0.4% |
Asset Composition Trend (2002–2024)
This chart illustrates how Biotest Aktiengesellschaft's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BIO market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biotest Aktiengesellschaft's current assets represent 56.5% of total assets in 2024, a decrease from 59.3% in 2002.
- Cash Position: Cash and equivalents constituted 7.5% of total assets in 2024, up from 2.2% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2002.
- Asset Diversification: The largest asset category is inventory at 33.4% of total assets.
Biotest Aktiengesellschaft Competitors by Total Assets
Key competitors of Biotest Aktiengesellschaft based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
Biotest Aktiengesellschaft - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.93 | 2.04 | 4.96 |
| Quick Ratio | 1.66 | 0.91 | 2.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €628.60 Million | €405.00 Million | €450.10 Million |
Biotest Aktiengesellschaft - Advanced Valuation Insights
This section examines the relationship between Biotest Aktiengesellschaft's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.28 |
| Latest Market Cap to Assets Ratio | 0.68 |
| Asset Growth Rate (YoY) | 1.6% |
| Total Assets | €1.43 Billion |
| Market Capitalization | $976.15 Million USD |
Valuation Analysis
Below Book Valuation: The market values Biotest Aktiengesellschaft's assets below their book value (0.68x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Biotest Aktiengesellschaft's assets grew by 1.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Biotest Aktiengesellschaft (2002–2024)
The table below shows the annual total assets of Biotest Aktiengesellschaft from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €1.43 Billion ≈ $1.68 Billion |
+1.64% |
| 2023-12-31 | €1.41 Billion ≈ $1.65 Billion |
+17.28% |
| 2022-12-31 | €1.20 Billion ≈ $1.41 Billion |
+8.95% |
| 2021-12-31 | €1.10 Billion ≈ $1.29 Billion |
-2.40% |
| 2020-12-31 | €1.13 Billion ≈ $1.32 Billion |
+2.07% |
| 2019-12-31 | €1.11 Billion ≈ $1.30 Billion |
+6.34% |
| 2018-12-31 | €1.04 Billion ≈ $1.22 Billion |
+6.52% |
| 2017-12-31 | €978.50 Million ≈ $1.14 Billion |
+4.90% |
| 2016-12-31 | €932.80 Million ≈ $1.09 Billion |
-3.11% |
| 2015-12-31 | €962.70 Million ≈ $1.13 Billion |
-6.77% |
| 2014-12-31 | €1.03 Billion ≈ $1.21 Billion |
+16.48% |
| 2013-12-31 | €886.50 Million ≈ $1.04 Billion |
+29.92% |
| 2012-12-31 | €682.35 Million ≈ $797.74 Million |
-0.06% |
| 2011-12-31 | €682.76 Million ≈ $798.22 Million |
+7.97% |
| 2010-12-31 | €632.34 Million ≈ $739.27 Million |
-0.18% |
| 2009-12-31 | €633.45 Million ≈ $740.57 Million |
+6.99% |
| 2008-12-31 | €592.04 Million ≈ $692.16 Million |
+10.31% |
| 2007-12-31 | €536.70 Million ≈ $627.46 Million |
+43.50% |
| 2006-12-31 | €374.01 Million ≈ $437.25 Million |
+1.88% |
| 2005-12-31 | €367.09 Million ≈ $429.17 Million |
+2.46% |
| 2004-12-31 | €358.27 Million ≈ $418.86 Million |
+2.37% |
| 2003-12-31 | €349.98 Million ≈ $409.16 Million |
-5.92% |
| 2002-12-31 | €371.99 Million ≈ $434.90 Million |
-- |
About Biotest Aktiengesellschaft
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for… Read more